We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 2.14 | 2.10 | 2.18 | 2.20 | 2.19 | 2.19 | 604,698 | 16:35:15 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Finance Services | 0 | -3.81M | -0.0114 | -1.93 | 7.33M |
TIDMIMM TIDMAV.
RNS Number : 0465W
Immupharma PLC
22 April 2016
RNS : FOR IMMEDIATE RELEASE 22 APRIL 2016
TR1 NOTIFICATION OF MAJOR INTEREST BY AVIVA
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces that it has received a TR-1 by Aviva plc and its subsidiaries, ("Aviva") confirming its holding in ImmuPharma of 11,285,180 Ordinary Shares. Aviva's current position in the Company is 9.27%.
Full disclosure of the TR1 is shown below:
Hot Features
Premium
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i)
--------------------------------------------------
1. Identity of the issuer or Immupharma plc
the underlying issuer
of existing shares to which
voting rights are
attached: (ii)
--------------------------------------------------------------- -------------------------------------
2 Reason for the notification (please tick the appropriate
box or boxes):
------------------------------------------------------------------------------------------------------
An acquisition or disposal of voting rights
------------------------------------------------------------------- ---------------------------------
An acquisition or disposal of qualifying financial
instruments which may result in the acquisition
of shares already issued to which voting rights
are attached
------------------------------------------------------------------- ---------------------------------
An acquisition or disposal of instruments with
similar economic effect to qualifying financial
instruments
------------------------------------------------------------------- ---------------------------------
An event changing the breakdown of voting rights
------------------------------------------------------------------- ---------------------------------
Other (please
specify):
----------------------------------------------------------- ------ ---------------------------------
3. Full name of person(s) Aviva plc & its subsidiaries
subject to the
notification obligation:
(iii)
------------------------------------------------------------- ---------------------------------------
4. Full name of shareholder(s) Registered Holder:
(if different from 3.):(iv)
BNY Norwich Union Nominees
Limited
628,858*
Chase (GA Group) Nominees
Limited
9,191,337*
*denotes direct interest
Chase (GA Group) Nominees
Limited
661,222
Chase Nominees Limited
275,292
Vidacos Nominees Limited
528,471
------------------------------------------------------------- ---------------------------------------
5. Date of the transaction 20 April 2016
and date on
which the threshold is
crossed or
reached: (v)
------------------------------------------------------------- ---------------------------------------
6. Date on which issuer 21 April 2016
notified:
------------------------------------------------------------- ---------------------------------------
7. Threshold(s) that is/are 7% to 8% Change at Direct
crossed or Interest Level
reached: (vi, vii)
------------------------------------------------------------- ---------------------------------------
8. Notified details:
---------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares (viii, ix)
---------------------------------------------------------------------------------------------------------------
Class/type Situation previous Resulting situation after
of to the triggering the triggering transaction
shares transaction
if possible
using
the ISIN
CODE
------------------- --------------------------------- -------------------------------------------------------
Number Number Number Number of % of voting
of of of voting rights (x)
Shares Voting shares rights
Rights
------------------- ------------------- ------------ ----------- ---------------------- ------------------
Direct Direct Indirect Direct Indirect
(xi) (xii)
------------------- ------------------- ------------ ----------- ---------- ---------- ------- ---------
Ordinary
Shares
GB0033711010 11,332,848* 11,332,848* 11,285,180 9,820,195 1,464,985 8.06% 1.21%
------------------- ------------ ----------- ---------- ---------- ------- ---------
* Includes right to recall loaned shares (100,000)
---------------------------------------------------------------------------------------------------------------
B: Qualifying Financial Instruments
---------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
---------------------------------------------------------------------------------------------------------------
Type of financial Expiration Exercise/ Number of voting % of voting
instrument date Conversion rights that rights
(xiii) Period (xiv) may be
acquired if
the
instrument
is
exercised/
converted.
------------------- ------------------- ------------------------- ---------------------- ------------------
C: Financial Instruments with similar economic effect
to Qualifying Financial Instruments (xv, xvi)
-----------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
-----------------------------------------------------------------------------------------------
Type of financial Exercise Expiration Exercise/ Number of voting % of voting
instrument price date Conversion rights instrument rights (xix,
(xvii) period refers to xx)
(xviii)
------------------ --------- ----------- ------------ ------------------- ----------------
Total (A+B+C)
------------------------------------------------------
Number of voting rights Percentage of voting rights
------------------------ ----------------------------
11,285,180 9.27%
------------------------ ----------------------------
9. Chain of controlled undertakings through which the
voting rights and/or the
financial instruments are effectively held, if applicable:
(xxi)
---------------------------------------------------------------------------------
The voting rights are managed and controlled by Aviva
Investors Global Services Limited, with the following
chain of controlled undertakings:-
Aviva Investors Global Services Limited:
* Aviva plc (Parent Company)
* Aviva Group Holdings Limited (wholly owned subsidiary
of Aviva plc)
* Aviva Investors Holdings Limited (wholly owned
subsidiary of Aviva Group Holdings Limited)
* Aviva Investors Global Services Limited (wholly owned
subsidiary of Aviva Investors Holdings Limited)
Proxy Voting:
---------------------------------------------------------------------------------
10. Name of the proxy holder: See Section 4
--------------------------------------------- ----------------------------------
11. Number of voting rights proxy
holder will cease to hold:
--------------------------------------------- ----------------------------------
(MORE TO FOLLOW) Dow Jones Newswires
April 22, 2016 04:50 ET (08:50 GMT)
12. Date on which proxy holder will
cease to hold
voting rights:
--------------------------------------------- ----------------------------------
13. Additional information: Figures are based the revised
total number of voting rights
of 121,781,219 as per the
recent Confirmation of EIS
and VCT Qualifying Status
and Issue of Equity announcement
of 01 March 2016.
--------------------------------------------- ----------------------------------
14. Contact name: Neil Whittaker, Aviva plc
--------------------------------------------- ----------------------------------
15. Contact telephone number: 01603 684420
--------------------------------------------- ----------------------------------
-Ends-
For further information please
contact:
+ 44 (0) 20
ImmuPharma plc (www.immupharma.org) 7152 4080
Tim McCarthy, Chairman
Lisa Baderoon, Head of Investor
Relations + 44 (0) 7721
Twitter: @immupharma 413496
Panmure, Gordon & Co., NOMAD & +44 (0) 20 7886
Broker 2500
Fred Walsh, Duncan Monteith, Corporate
Finance
Charles Leigh-Pemberton, Corporate
Broking
Notes to Editors
ImmuPharma PLC
ImmuPharma is a pharmaceutical development company listed since 2006 on AIM of the London Stock Exchange (LSE:IMM), focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. ImmuPharma is led by a commercially focused Board and management team with extensive experience.
ImmuPharma announced on 1 March 2016 the successful completion of a GBP8.4 million fund raise, comprising a Placing and Subscription together with confirmation of EIS and VCT qualifying status. Monies raised will principally be used to complete the pivotal Phase III trial of Lupuzor(TM). Following the issue of the New Ordinary Shares referred to above, ImmuPharma will have 121,781,219 ordinary shares of 10 pence each (the "Ordinary Shares") in issue.
Lupuzor(TM)
Lupuzor(TM) (also referred to as forigerimod, rigerimod, IPP-201101 or P140 is ImmuPharma's lead compound and a potential treatment for lupus (or Systemic Lupus Erythematosus), a chronic, potentially life-threatening auto-immune disease. Lupuzor(TM) has a novel mechanism of action aimed at modulating the body's immune system so that it does not attack healthy cells, and avoids causing adverse side effects. It has the potential to halt the progression of the disease in a substantial proportion of patients.
Lupuzor(TM) has been granted Fast Track status by the US FDA and approval to start Phase III under Special Protocol Assessment (SPA). This SPA was subsequently amended due to its strong safety and efficacy profile to allow for a reduced number of patients in the pivotal Phase III trial thereby reducing the projected cost and time of development considerably.
The pivotal Phase III clinical study is entitled "A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus". It is a pivotal study designed to demonstrate the safety and efficacy of IPP-201101 and as a last step prior to the filing of the drug for approval with the US Food & Drug Administration ("FDA") and the European Medicines Agency ("EMA"). For more information please visit: www.ClinicalTrials.gov/lupuzor
Commercial Opportunity
There are an estimated five million people globally suffering from Lupus, with approximately 1.5 million patients in the US, Europe and Japan (Source: Lupus Foundation of America). Current 'standard of care' treatments, including steroids and immunosuppressants, can potentially have either serious side effects for patients or limited effectiveness, with over 60% of patients not adequately treated. GSK's Benlysta is the first Lupus drug approved in over 50 years and paves the path to market for Lupuzor(TM). Based on conservative estimates, and taking into account that Benlysta is priced currently at approximately $35,000 per patient per year, Lupuzor(TM) would be entering a market with the potential for multi-billion dollar sales. For more information on Lupuzor(TM) please visit: www.lupuzor.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLVLLBLQZFZBBZ
(END) Dow Jones Newswires
April 22, 2016 04:50 ET (08:50 GMT)
1 Year Immupharma Chart |
1 Month Immupharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
